Phase Forward, SGS Sign Mega Deal
Phase Forward and SGS Life Science Services have extending their existing partnership via a mulit-year, multimillion dollar agreement. SGS has been a Phase Forward customer since 2002 and as an EU-based data management CRO, manges nearly 100 clinical trials, processing over one million CRF pages per year.
The agreement offers SGS' customers the benefits of Phase Forward's solutions including InForm™ Global Trial Management (GTM), Clarix™ Interactive Response Technology (IRT) and Maaguzi Web-based electronic patient reported outcomes (ePRO) and late phase solutions.
“Our customers are looking for an integrated eClinical solution comprising multiple systems,” said Luc Braeken, global director, Biometrics Services, SGS. “The agreement announced today will allow us to respond to customer demand for this integrated solution with innovative product sets from a market leader. This solution is designed to meet the needs of even the most demanding clinical development professional, offering more effective ways to manage clinical operations, help ensure product safety and reduce time-to-market.”
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
